[A quantitative immunohistochemical analysis of bone morphogenetic protein (BMP) in osteosarcoma of jaw].
The monoclonal antibody against bone morphogenetic protein (BMP-McAb) was first used for demonstration of bone morphogenetic protein (BMP) in 13 patients with osteosarcoma. Using avidin-biotin complex method (ABC), we demonstrated that BMP mainly existed in the tumor cell cytoplasm and tumorous osteoblast with positive staining in 10 out of 13 osteosarcoma patients. Using this staining method, we can not only differentiate osteosarcoma from fibrosarcoma (all are negative) and other non-osteogenic tumors, but also further classify osteosarcoma according to the BMP content and distribution by means of quantitative histological analysis. The BMP quantity of osteosarcoma with the patients' clinical situation will be useful in clinical diagnosis, treatment and prognosis. The relationship between BMP and the formation of the tumorous bone, and the relation between BMP and the process of osteosarcoma are discussed.
Jin
Y
Y
College of the Fourth Military Medical University, Xi'an.
D000293:Adolescent; D000328:Adult; D019485:Bone Morphogenetic Proteins; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008339:Mandibular Neoplasms / Q000737:chemistry*; D008441:Maxillary Neoplasms / Q000737:chemistry*; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis*; D012516:Osteosarcoma / Q000737:chemistry* / Q000145:classification; D011506:Proteins / Q000032:analysis*
D019485:Bone Morphogenetic Proteins; D009363:Neoplasm Proteins; D011506:Proteins